ImpediMed
| File:ImpediMed-website-logo.png | |
| Publicly Traded | |
| ISIN | 🆔 |
| Industry | Medical Appliances & Equipment |
| Founded 📆 | Brisbane, QLD, Australia (1999) |
| Founder 👔 | |
| Headquarters 🏙️ | Unit 1, 50 Parker Court, , |
Number of locations | 4 (2016) |
Area served 🗺️ | Global |
Key people | |
| Products 📟 |
|
| Members | |
Number of employees | 60 (2016) |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
ImpediMed is an Australian medical device manufacturing company headquartered in Brisbane, Queensland. ImpediMed has offices in Carlsbad, California and Bloomington, Minnesota, as well as in Europe. The company is known primarily for its fluid status and body composition analysis devices, which utilize bioimpedance spectroscopy (BIS) technology.
History[edit]
ImpediMed was founded in 1999 as ImpediMed Ltd. Soon after its founding, the company worked closely with Associate Professor Leigh Ward of the University of Queensland to develop and commercialize devices incorporating bioimpedance spectroscopy (BIS) technology.[1] The practical applications of this technology include body composition analysis and lymphedema detection.
ImpediMed launched the DF50 and SFB7, the company's first body composition monitors, in 2005. These were among the first portable devices able to use bioimpedance analysis (BIA) technology to accurately measure multiple components of body composition. The L-Dex U400, the most recent Impedimed device, uses BIS to detect lymphedema up to 10 months earlier than other methods.[1]
In October 2007, ImpediMed Ltd. was officially listed on the Australian Stock Exchange.[2] Shortly thereafter, ImpediMed finalized their acquirement of California-based company XITRON Technologies.[3] With this acquisition, ImpediMed gained the ability to market their products in the United States.
After a pilot program in six US-based cancer centers, the L-Dex was commercially released in the United States in January 2016.[4] It has since been adopted by successful hospitals and clinics; Mayo Clinic entered a clinical trial agreement with ImpediMed to explore additional possibilities for their BIS technology.[5] In June 2016, ImpediMed announced the opening of their Minnesota office.[6] It was then officially launched in August 2016.[7][8]
References[edit]
- ↑ 1.0 1.1 "ATSE Clunies Ross Awards Dinner 2015". ATSE. Retrieved 14 July 2016.
- ↑ Phil Auckland (22 October 2007). "ImpediMed Admitted to ASX Official List Today 22nd October 2007". ImpediMed Limited. Retrieved 14 July 2016.
- ↑ "ImpediMed Completes US Acquisition of XITRON Technologies" (PDF). ImpediMed Limited. 26 October 2007. Retrieved 14 July 2016.
- ↑ "ImpediMed Announces U.S. Commercial Launch of L-Dex® System for Assessment of Lymphedema in Cancer Survivors" (PDF). ImpediMed Limited. 7 January 2016. Retrieved 14 July 2016.
- ↑ "ImpediMed Signs Five Year, Multi-Location Clinical Trial Agreement with Mayo Clinic" (PDF). ImpediMed Limited. 31 May 2016. Retrieved 14 July 2016.
- ↑ "Australian Medical Technology Company Opens Minnesota Office" (PDF). ImpediMed Limited. 8 June 2016. Retrieved 14 July 2016.
- ↑ Sarah-Jane Tasker (3 August 2016). "ImpediMed unveils its game changer: Sozo". The Australian. Retrieved 11 August 2016.
- ↑ "SOZO™ Launched - First Product for Health and Wellness Markets". Yahoo Inc. 11 August 2016. Retrieved 11 August 2016.
External links[edit]
This article "ImpediMed" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
